keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant in lung cancer

keyword
https://www.readbyqxmd.com/read/28918673/suppression-of-tgf-%C3%AE-1-enhances-chemosensitivity-of-cisplatin-resistant-lung-cancer-cells-through-the-inhibition-of-drug-resistant-proteins
#1
Jin Wang, Yunqing Chen, Fenggang Xiang, Min Li, Hong Li, Jinghua Chi, Keyu Ren
Cisplatin-based chemotherapy is the first-line treatment for non-small cell lung cancer (NSCLC), but drug resistance occurs in most patients, leading to treatment failure. Recent studies have shown that epithelial-mesenchymal transition (EMT) is associated with drug resistance. However, the underlying mechanism is not entirely clear. In this study, first we showed significant positive correlation between the expression of ERCCl and vimentin, and significant negative correlation between the ERCCl and E-cadherin in the neoadjuvant chemotherapy group and the simple surgery group...
September 18, 2017: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/28900290/alteration-of-pd-l1-expression-and-its-prognostic-impact-after-concurrent-chemoradiation-therapy-in-non-small-cell-lung-cancer-patients
#2
Daichi Fujimoto, Keiichiro Uehara, Yuki Sato, Ichiro Sakanoue, Munehiro Ito, Shunsuke Teraoka, Kazuma Nagata, Atsushi Nakagawa, Yasuhiro Kosaka, Kojiro Otsuka, Yukihiro Imai, Hiroshi Hamakawa, Yutaka Takahashi, Masaki Kokubo, Keisuke Tomii
Concurrent chemoradiation therapy (CCRT) is the treatment of choice for locally advanced non-small cell lung cancer (LA-NSCLC). Several clinical trials that combine programmed cell death 1 (PD-1) axis inhibitors with radiotherapy are in development for patients with LA-NSCLC. However, the effect of CCRT on programmed cell death ligand-1 (PD-L1) expression on tumor cells is unknown. In this study, we analysed paired NSCLC specimens that had been obtained pre- and post-CCRT. PD-L1 expression on tumor cells was studied by immunohistochemistry...
September 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28890815/the-role-of-neoadjuvant-radiotherapy-for-locally-advanced-rectal-cancer-with-resectable-synchronous-metastasis
#3
Croix C Fossum, Jasim Y Alabbad, Lindsay B Romak, Christopher L Hallemeier, Michael G Haddock, Marianne Huebner, Eric J Dozois, David W Larson
BACKGROUND: Although neoadjuvant radiotherapy is typically administered for locally-advanced rectal cancer to reduce local recurrence (LR), its role for patients who present with synchronous resectable liver and/or lung metastasis is not well defined. The aim of this study was to evaluate the role of neoadjuvant radiotherapy for patients with stage IV rectal cancer undergoing curative-intent surgery. METHODS: This study is a retrospective review of a prospectively maintained surgical registry of all consecutive adult patients who underwent curative-intent resection at Mayo Clinic in Rochester, MN, from January 1990 until December 2014 with a median follow-up time of 43 (IQR 16-67) months...
August 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28853141/influence-of-tumor-response-and-treatment-schedule-on-the-distribution-of-tumor-recurrence-in-esophageal-cancer-patients-treated-with-neoadjuvant-chemoradiotherapy
#4
Kristien M Jipping, Jan Binne Hulshoff, Evita A van Amerongen, Tim I Bright, David I Watson, John Th M Plukker
BACKGROUND AND OBJECTIVES: The impact of different neoadjuvant chemoradiotherapy (nCRT) schedules and pathologic complete response (pCR) on the distribution of recurrence is unclear in esophageal cancer (EC). We assessed the effect of pCR and nCRT schedule in EC. METHODS: Patients with T1N+/T2-4aN0-3/M0 EC treated in different centers, with either carboplatin/paclitaxel/41.4 Gy (CROSS: n = 134) or Cisplatin/5-fluorouracil/45-50.4 Gy (Cis/5FU: n = 88) followed by surgery were included...
August 29, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28838509/initial-experience-with-lung-cancer-resection-after-treatment-with-t-cell-checkpoint-inhibitors
#5
Jamie E Chaft, Matthew D Hellmann, Moises J Velez, William D Travis, Valerie W Rusch
T-cell checkpoint inhibitors targeting the programmed death receptor-1 (PD-1) and its ligand (PD-L1) have recently been approved for the treatment of metastatic non-small cell lung cancer (NSCLC), but their safety and efficacy as neoadjuvant therapy are still undefined. Autoimmune toxicities, notably pneumonitis, are a particular concern in the perioperative setting. This series of 5 cases describes for the first time the safety and technical issues relating to pulmonary resection after checkpoint inhibitor therapy...
September 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/28827262/polymorphisms-of-the-stem-cell-marker-gene-cd133-are-associated-the-clinical-outcome-in-a-cohort-of-chinese-non-small-cell-lung-cancer-patients
#6
Qing-Feng Liu, Zhi-Fei Zhang, Guang-Jie Hou, Guang-Yu Yang, Yi He
OBJECTIVES: To evaluate the prognostic relevance of four functional single nucleotide polymorphisms (SNPs) in CD133 (rs2240688A>C, rs10022537T>A, rs7686732C>G, and rs3130C>T) on overall survival (OS) of non-small cell lung cancer (NSCLC) patients. DESIGN: Retrospective cohort study. SETTING: Department of General Surgery, in a general hospital, Henan Province, China. PARTICIPANTS: NSCLC patients aged ≥18 years, who were not receiving preoperative neoadjuvant therapies and had a blood sample available for genotyping, were eligible for inclusion...
August 21, 2017: BMJ Open
https://www.readbyqxmd.com/read/28819411/comprehensive-study-of-prognostic-risk-factors-of-patients-underwent-pneumonectomy
#7
Chang Gu, Rui Wang, Xufeng Pan, Qingyuan Huang, Jizhuang Luo, Jiajie Zheng, Yiyang Wang, Jianxin Shi, Haiquan Chen
Introduction: To investigate postoperative complications and the prognostic risk factors of patients underwent pneumonectomy. Methods: Four hundred and six patients underwent pneumonectomy were subjected to the study. All the clinicopathologic data including age, gender, smoking history, surgical treatment, postoperative complications, tumor staging and the follow-up information were investigated. Results: The 30-day and 90-day mortality rates were 3.2% and 6.2%, respectively. Postoperative complications developed in 149 patients (36...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28808224/off-label-use-of-crizotinib-as-a-neoadjuvant-treatment-for-a-young-patient-when-conventional-chemotherapy-gave-no-benefits-in-stage-iiia-non-small-cell-lung-cancer
#8
Delphine Dumont, Pascal Dô, Delphine Lerouge, Gaëtane Planchard, Marc Riffet, Catherine Dubos-Arvis, Serge Danhier, Radj Gervais
BACKGROUND The treatment of locally advanced non-small cell lung cancer involves a combination of chemotherapy, surgery, and radiotherapy. Each case is discussed and the best strategy is chosen individually, following international guidelines. CASE REPORT A 37-year-old man was diagnosed with locally advanced broncho-pulmonary adenocarcinoma (stage IIIA). The disease was stable after 2 cycles of cisplatin plus Navelbine used as neoadjuvant therapy. FISH analysis revealed an ALK rearrangement. The patient then received unlicensed crizotinib as second-line neoadjuvant treatment, which led to an almost complete radiological and metabolic response...
August 15, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28806990/dvh-and-ntcp-based-dosimetric-comparison-of-different-longitudinal-margins-for-vmat-imrt-of-esophageal-cancer
#9
S Münch, M Oechsner, S E Combs, D Habermehl
PURPOSE: To cover the microscopic tumor spread in squamous cell carcinoma of the esophagus (SCC), longitudinal margins of 3-4 cm are used for radiotherapy (RT) protocols. However, smaller margins of 2-3 cm might be reasonable when advanced diagnostic imaging is integrated into target volume delineation. Purpose of this study was to compare the dose distribution and deposition to the organs at risk (OAR) for different longitudinal margins using a DVH- and NTCP-based approach. METHODS: Ten patients with SCC of the middle or lower third were retrospectively selected...
August 15, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28803721/conditioning-neoadjuvant-therapies-for-improved-immunotherapy-of-cancer
#10
REVIEW
Zachary Benson, Saeed H Manjili, Mehran Habibi, Georgi Guruli, Amir A Toor, Kyle K Payne, Masoud H Manjili
Recent advances in the treatment of melanoma and non-small cell lung cancer (NSCLC) by combining conventional therapies with anti-PD1/PD-L1 immunotherapies, have renewed interests in immunotherapy of cancer. The emerging concept of conventional cancer therapies combined with immunotherapy differs from the classical concept in that it is not simply taking advantage of their additive anti-tumor effects, but it is to use certain therapeutic regimens to condition the tumor microenvironment for optimal response to immunotherapy...
August 10, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28741246/successful-resection-after-neoadjuvant-chemotherapy-for-esophageal-cancer-with-posterior-thoracic-paraaortic-lymph-node-metastasis-a-case-report-and-literature-review
#11
Yuji Shishido, Hiroshi Miyata, Keijirou Sugimura, Masaaki Motoori, Norikatsu Miyoshi, Masayoshi Yasui, Takeshi Omori, Masayuki Ohue, Yoshiyuki Fujiwara, Masahiko Yano
Metastasis to the posterior thoracic paraaortic lymph nodes rarely occurs in esophageal cancer, and a treatment strategy has not been established. We treated two cases of esophageal cancer with this type of metastasis; in both cases, we successfully performed surgical resection after neoadjuvant chemotherapy. In case 1, the patient received neoadjuvant chemotherapy, which consisted of docetaxel, cisplatin and 5-fluorouracil, and then underwent dissection of the posterior thoracic paraaortic lymph nodes. The left thoracic approach was used together with subtotal esophagectomy via a right thoracotomy...
July 24, 2017: General Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28734185/primary-small-cell-neuroendocrine-carcinoma-of-the-breast-a-case-report-and-review-of-the-literature
#12
Abigail Tremelling, Selyne Samuel, Mary Murray
INTRODUCTION: Primary small cell neuroendocrine carcinoma of the breast (SCNCB) is a very uncommon type of breast cancer. Histology and morphology are virtually indistinguishable from small cell neuroendocrine carcinomas of the lung (SCNCL), mandating a search for a primary site elsewhere in the body. There is no standard approach to treatment as there are only a limited number of cases reported in the literature. This report summarizes a case of primary SCNCB and presents a review of the literature...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28733185/fdg-pet-parameters-as-predictors-of-pathologic-response-and-nodal-clearance-in-patients-with-stage-iii-non-small-cell-lung-cancer-receiving-neoadjuvant-chemoradiation-and-surgery
#13
Andrea L Arnett, Ann T Packard, Kristin Mara, Aaron S Mansfield, Dennis A Wigle, Michael G Haddock, Sean S Park, Kenneth R Olivier, Yolanda I Garces, Kenneth W Merrell
OBJECTIVE: Pathologic complete response (pCR) following neoadjuvant chemoradiation (CRT) is associated with improved outcomes in stage III non-small cell lung cancer. Conflicting results exist regarding the value of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) in predicting pCR. This study evaluated the association between post-CRT FDG-PET and pCR using novel FDG-PET parameters. METHODS AND MATERIALS: This retrospective study included patients treated with CRT and resection...
April 19, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28687838/development-and-validation-of-an-individualized-immune-prognostic-signature-in-early-stage-nonsquamous-non-small-cell-lung-cancer
#14
Bailiang Li, Yi Cui, Maximilian Diehn, Ruijiang Li
Importance: The prevalence of early-stage non-small cell lung cancer (NSCLC) is expected to increase with recent implementation of annual screening programs. Reliable prognostic biomarkers are needed to identify patients at a high risk for recurrence to guide adjuvant therapy. Objective: To develop a robust, individualized immune signature that can estimate prognosis in patients with early-stage nonsquamous NSCLC. Design, Setting, and Participants: This retrospective study analyzed the gene expression profiles of frozen tumor tissue samples from 19 public NSCLC cohorts, including 18 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort...
July 6, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28675081/neoadjuvant-chemotherapy-by-bronchial-arterial-infusion-in-patients-with-unresectable-stage-iii-squamous-cell-lung-cancer
#15
Jun Zhu, Hai-Ping Zhang, Sen Jiang, Jian Ni
BACKGROUND: We investigated the effects of neoadjuvant chemotherapy administered via bronchial arterial infusion (BAI) on unresectable stage III lung squamous cell carcinoma (SCC). METHODS: This was a single-arm retrospective study of chemotherapy with gemcitabine plus cisplatin (GP) administered via BAI to patients with unresectable lung SCC. Data regarding the post-treatment response rate, downstage rate, and surgery rate, as well as progression-free survival (PFS), overall survival (OS), quality of life, and post-BAI side effects were collected...
July 1, 2017: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/28671758/comparison-of-mediastinal-lymph-node-status-and-relapse-pattern-in-clinical-stage-iiia-non-small-cell-lung-cancer-patients-treated-with-neoadjuvant-chemotherapy-versus-upfront-surgery-a-single-center-experience
#16
Milan Savic, Milica Kontic, Maja Ercegovac, Jelena Stojsic, Slavisa Bascarevic, Dejan Moskovljevic, Marko Kostic, Radomir Vesovic, Spasoje Popevic, Marija Laban, Jelena Markovic, Dragana Jovanovic
BACKGROUND: In spite of the progress made in neoadjuvant therapy for operable non small-cell lung cancer (NSCLC), many issues remain unsolved, especially in locally advanced stage IIIA. METHODS: Retrospective data of 163 patients diagnosed with stage IIIA NSCLC after surgery was analyzed. The patients were divided into two groups: a preoperative chemotherapy group including 59 patients who received platinum-etoposide doublet treatment before surgery, and an upfront surgery group including 104 patients for whom surgical resection was the first treatment step...
September 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28670371/circulating-tumor-cells-what-we-know-what-do-we-want-to-know-about-them-and-are-they-ready-to-be-used-in-clinics
#17
Zuzana Bielčiková, Anna Jakabová, Michael Pinkas, Milada Zemanová, Katarína Kološtová, Vladimír Bobek
Circulating tumor cells (CTC) present in peripheral blood are assigned precursors of advanced tumor disease. Simplicity of blood withdrawal procedure adds practically an unlimited possibility of the CTC-monitoring and the advantages of the repeated biopsies over time. CTC got prognostic, predictive and diagnostic status with the technologic advance. Although the clinical utility of CTC has reached the high evidence, the significance of CTC testing was presented in the treatment strategy mostly with palliative intention...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28643244/durvalumab-first-global-approval
#18
Yahiya Y Syed
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy...
August 2017: Drugs
https://www.readbyqxmd.com/read/28621292/is-endobronchial-ultrasound-guided-transbronchial-needle-aspiration-an-effective-diagnostic-procedure-in-restaging-of-non-small-cell-lung-cancer-patients
#19
Erdoğan Cetinkaya, Ozan Usluer, Aydın Yılmaz, Nuri Tutar, Ertan Çam, Mehmet Akif Özgül, Nilgün Yılmaz Demirci
BACKGROUND AND OBJECTIVES: Selecting the diagnostic procedure for mediastinal restaging after chemotherapy and/or radiotherapy in Stage IIIA-N2 non-small cell lung cancer (NSCLC) patients remains a problem. The aim of the study was to determine the efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the evaluation of mediastinal lymph nodes in the restaging of NSCLC patients. MATERIALS AND METHODS: The present multicentric study retrospectively analyzed the results of Stage IIIA-N2 NSCLC patients who had undergone EBUS for mediastinal restaging after preoperative chemotherapy or radiotherapy or both...
May 2017: Endoscopic Ultrasound
https://www.readbyqxmd.com/read/28615970/changes-in-pulmonary-function-tests-in-breast-carcinoma-patients-treated-with-locoregional-post-mastectomy-radiotherapy-results-of-a-pilot-study
#20
Eyad Fawzi AlSaeed, Faisal Khalid Balaraj, Mutahir A Tunio
BACKGROUND: The aim of present pilot study was to evaluate the changes in pulmonary function tests (PFTs) after locoregional post-mastectomy radiotherapy (PMRT) in breast cancer patients. MATERIALS AND METHODS: Twenty consecutive patients with histopathologically confirmed breast carcinoma stages T1-T4, N1-N2, who were treated with modified radical mastectomy with neoadjuvant or adjuvant chemotherapy underwent PFTs, including forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced expiratory flow at 50%, and peak expiratory flow rate, maximum mid expiratory flow (MMEF25-75), maximal oxygen consumption (VO2max), and carbon monoxide diffusing capacity (DLCO) before, at 30 days, and at 90 days after locoregional PMRT...
2017: Breast Cancer: Targets and Therapy
keyword
keyword
52784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"